Post sponsored by

MIL OSI Translation. Region: Germany / Deutschland –

Source: Federal Ministry for Economic Affairs and Energy

10/14/2020 – Press release – Innovation funding


A vaccination project funded by the EXIST program of the Federal Ministry for Economic Affairs and Energy is developing a second-generation COVID-19 vaccine. The start-up “Prime Vector Technologies – PVT” from Tübingen was able to demonstrate how scientific potential can be used in Germany. With this new generation of vaccines, the SARS-CoV-2 variants that are now the most widespread are directly addressed. In addition to the strongest and broadest possible antibody-based immune response, SARS-CoV-2-specific T cells are formed. This also increases protection against any mutations in the virus. Another declared goal for the next generation of vaccines is the provision of a suitable booster immunization as soon as the antibody response in COVID-19 sick or immunized people drops. Federal Minister of Economics Peter Altmaier is delighted with the current SARS-CoV-2 vaccine development and explains: “Germany is at the forefront of the development of second-generation vaccines with the EXIST-funded vaccine project from Prime Vector Technologies. We are very pleased because research and innovations are central in the fight against COVID-19. ”With a further increase of 18 million euros, the BMWi is supporting the EXIST start-up project to examine the vaccine candidate developed in Tübingen in the first two clinical phases on humans . PVT’s vaccine candidate could enter the approval process towards the end of 2021. Peter Kremsner, head of an EU vaccine study at the University Hospital Tübingen, a renowned expert has said positively about the polyvalent COVID-19 vaccine candidate. “With the vaccine candidate from the EXIST spin-off PVT, the University Hospital Tübingen is strengthening its position as one of the global centers in COVID-19 vaccine development,” said Prof. Dr. Kremsner. The new vaccine concept is also attracting wide attention internationally. A Southeast Asian pharmaceutical company is very interested in licensing with the aim of large-scale vaccine production in 2021. To supply the German population, the BMWi has secured the provision of vaccine doses free of license fees at PVT. With the EXIST program, it promotes “business start-ups from science” The BMWi has been successful start-up spin-offs from the German university and science landscape for 20 years. For more information on the three EXIST program lines, click here


EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.

MIL Translation OSI